Tel Aviv, Israel – October 01, 2026 -- Lutris Pharma reported that its topical B-Raf inhibitor LUT014 achieved Treatment Success in 71.8% of patients with EGFR inhibitor-induced acneiform rash, compared with 38.5% on placebo (p=0.003), in updated Phase 2 data presented at the 35th EADV Congress in Vienna.